Gut-Brain Axis Therapeutics is developing microbiota transplant therapy for treating gut-brain disorders in autism and related conditions. The company’s founding is deeply personal. Dr. James Adams, who leads the organization, has a daughter with autism, which motivated him 25 years ago to focus his research on treatments for the condition. 15 years ago, he led a study which demonstrated that gastrointestinal symptoms strongly correlated with autism symptoms, and that children with autism were missing beneficial bacteria and had harmful yeast. That led to their first clinical trial of microbiota transplant, which was very successful and led to 5 more, with the last 2 funded by Gut-Brain Axis Therapeutics.Continue reading→

Memorial Day is a time to remember and honor the men and women who gave their lives in military service to our country. Some died in war time, others died in peacetime. Some died in foreign lands, others died right here at home. We also remember service members who through their injuries, exposure to toxins, or wartime experiences had lives that ended too soon even though they made it home alive. Their sacrifice is the highest price that can be paid for the opportunities we have as Americans. Today, we remember them, honor them, and most if all, should be thankful for the lives that they lived and the sacrifice that they made for us.Continue reading→

Chronic HDV is considered the most severe form of viral hepatitis due to rapid disease progression towards liver failure and liver-related death –

– Approval introduces the first FDA-approved therapy for this disease with limited treatment options and high unmet need
Continue reading→

For the second straight year, the University of Arizona College of Medicine – Phoenix hosted Research Week. The series of events, bridged between two weeks, served as a fantastic showcase for how the college and its partners are driving discovery and fueling the future of healthier Arizona.Continue reading→

Global coalition unites NAMs developers to accelerate validation, qualification, and regulatory adoption of human-relevant methodologies, reducing reliance on animal models and improving the efficiency of drug development.Continue reading→

Christopher K. Finch, Pharm.D., FCCM, FCCP has been appointed dean of the R. Ken Coit College of Pharmacy, effective Aug. 1, following a collaborative and comprehensive national search that involved the broader campus community.Continue reading→

His lab will focus on advancing immuno‑oncology and microbiome innovation and research on understanding and interrupting tumor–immune interactionsContinue reading→

Dr. Nageatte Ibrahim helped guide the clinical development of Keytruda, one of the most consequential immuno-oncology therapiesContinue reading→

HemaSense is developing a wearable device designed to give clinicians real-time visibility into what’s happening beneath the skin during post-procedural recovery, with a mission to accelerate recovery through actionable clinical insight.Continue reading→